2-OH-E1 % (Pre-menopausal)

Optimal result: 50 – 85 %

A decreased 2-OH-E1 % means a smaller share of your estrone is being metabolized through the 2-hydroxylation route and more is being shunted toward 4-OH and/or 16-OH pathways. It does not mean your overall estrogen is low—it reflects how your body is processing estrogen, not how much you make.

Why it can be low

  • Enzyme balance: Relatively lower activity of Phase I enzymes that favor 2-hydroxylation (e.g., CYP1A family), or relatively higher activity of pathways that form 16-OH or 4-OH metabolites.

  • Lifestyle and diet: Low intake of cruciferous vegetables (broccoli, kale, cabbage), low overall plant diversity/fiber, high alcohol intake, or high exposure to environmental stressors can shift pathway percentages.

  • Medications/supplements: Enzyme inducers/inhibitors (various prescription meds and botanicals) may alter Phase I balance; hormonal contraception/HRT changes the whole estrogen milieu and its metabolites.

  • Collection/timing: Non–first-morning samples, very dilute urine, or different cycle days can nudge borderline percentages. Always compare to your lab’s reference range.

How to read your result

  • Mildly low: Common and often transient. Re-check with an optimized collection to confirm.

  • Persistently low: Look at the pattern with partner markers—16-OH-E1 %, 4-OH-E1 %, and 2-methoxy metabolites. A low 2-OH-E1 % with high 16-OH suggests a different plan than a low 2-OH with high 4-OH.

  • Remember: This marker does not diagnose disease or predict cancer risk on its own. It’s a metabolism snapshot to guide sensible, food-first adjustments and, when appropriate, targeted clinical follow-up.

Practical next steps

  1. Confirm correctly: Repeat using a first-morning urine sample, keep collection consistent (many labs prefer early follicular phase), and limit alcohol for 24–48 hours beforehand.

  2. Review the pattern: Check 16-OH-E1 %, 4-OH-E1 %, and 2-methoxy metabolites to see where estrogen is being routed and whether methylation (COMT) looks supported.

  3. Food-first support for balance:

    • Emphasize cruciferous vegetables and overall plant diversity.

    • Aim for 25–35 g/day of fiber, adequate protein, and hydration to support Phase II clearance.

    • Moderate alcohol; prioritize sleep and regular activity.

  4. Consider supplements only with your clinician: Compounds like I3C/DIM can tilt metabolism toward 2-hydroxylation but aren’t for everyone; re-test rather than self-treat.

  5. Medication and exposure check: Discuss prescription meds/botanicals that influence liver enzymes; address tobacco smoke and other exposures that skew Phase I/II balance.

Key takeaways

  • Decreased 2-OH-E1 % reflects a relative shift away from the 2-hydroxylation route; it does not equal “low estrogen.”

  • Interpret in context with 16-OH, 4-OH, and 2-methoxy partners, your symptoms, and cycle timing.

  • Focus on balanced pathways via food-first strategies and clinician-guided changes; confirm improvements with a repeat test.

2-OH-E1 % (Pre-menopausal) shows what share of estrone is routed down the 2-hydroxylation pathway to 2-hydroxyestrone—a distribution metric, not a disease diagnosis. A lower percentage suggests a relative shift toward 4-/16-hydroxylation, while a higher percentage indicates more 2-OH routing, which is generally fine if 2-methoxy metabolites are adequate (reflecting healthy COMT/methylation). Your result can be influenced by diet (crucifers, I3C/DIM), alcohol, medications/smoking, cycle timing, and collection quality. Interpret against your lab’s reference range, aim for balanced pathways (not “max 2-OH”), and consider food-first methylation support, fiber, sleep, stress management, and clinician guidance if patterns are off.

2-OH-E1 % is the percentage of estrone (E1) that your body converts down the 2-hydroxylation pathway to 2-hydroxyestrone. It’s a distribution marker, not a raw hormone level: it shows how your estrogen metabolism is partitioned among pathways (2-OH, 4-OH, 16-OH). Results are reported from a spot urine sample, typically normalized to creatinine, so hydration has less impact.

Why it matters

Your body breaks down estrogens through several Phase I pathways:

  • 2-hydroxylation (this marker): makes 2-hydroxyestrone, a less estrogenic “catechol” estrogen. It is usually considered a benign/neutral route when it is subsequently methylated by COMT to 2-methoxy metabolites.

  • 4-hydroxylation: produces reactive catechols that can form quinones if not well methylated/neutralized.

  • 16-hydroxylation: yields 16α-OH-E1, a more estrogenic metabolite that can act longer at receptors.

A healthy pattern is balanced, within your lab’s reference ranges. This marker does not diagnose cancer risk and shouldn’t be used alone to predict disease—it’s a metabolic snapshot that helps you and your clinician see where estrogen is being routed.

How to read your result (always use your lab’s reference range)

  • Lower 2-OH-E1 % (shift away from 2-pathway):
    Suggests a relative preference for 16-OH and/or 4-OH pathways. In context with other metabolites, this may reflect lower CYP1A activity, certain medications, or lifestyle factors. Clinically, the goal is not “max 2-OH,” but an appropriate balance with good downstream neutralization (methylation, glucuronidation, sulfation).

  • Higher 2-OH-E1 % (shift toward 2-pathway):
    Indicates more estrone is routed to 2-hydroxylation. On its own, that’s often fine—especially if 2-methoxy metabolites are also adequate (showing COMT is methylating well). If 2-OH-E1 % is high but 2-methoxy levels are low, discuss methylation support and overall antioxidant status with your clinician.

Pair this marker with its “downstream” partner. High 2-OH alongside low 2-methoxy suggests bottlenecks in methylation (COMT); low 2-OH with high 16-OH shows a different pattern and a different plan.

What can influence 2-OH-E1 %

  • Dietary patterns: Cruciferous vegetables (broccoli, kale, cabbage), I3C/DIM supplements, and a diet rich in polyphenols can tilt metabolism toward 2-hydroxylation; always use supplements judiciously and with clinician guidance.

  • Alcohol, caffeine, tobacco smoke, and charred foods: Can modify CYP enzymes (Phase I) and shift pathway percentages.

  • Medications/supplements: Certain drugs (e.g., enzyme inducers/inhibitors), proton-pump inhibitors, St. John’s wort, and others may change Phase I/II balance. Hormonal contraception and HRT alter overall estrogen production and metabolite patterns.

  • Methylation capacity (COMT) & Phase II pathways: Adequate folate, B12, B6, magnesium, and choline/betaine support methylation; fiber and hydration aid glucuronidation/excretion.

  • Cycle timing & collection: Aim for consistent timing (many labs prefer early follicular) and a first-morning urine sample for comparisons.

What to do next (actionable plan)

If your 2-OH-E1 % is low (relative shift to 16-/4-OH):

  1. Recheck under optimal collection conditions; 2) Review medications and alcohol/smoking; 3) Discuss with your clinician adding/lifestyle sources of crucifers and overall plant diversity; 4) Ensure adequate fiber (25–35 g/day), sleep, and exercise, which support Phase II clearance; 5) Consider whether I3C/DIM is appropriate (clinician-guided), especially if 16-OH is relatively high.

If your 2-OH-E1 % is high:

  1. Confirm that 2-methoxy metabolites are also sufficient—good methylation helps neutralize catechols; 2) If methoxy is low, prioritize methylation nutrients (food-first; supplements only with guidance), manage alcohol, and consider stress/sleep optimization; 3) Keep perspective—a high percentage alone isn’t harmful, but balance across pathways matters.

If any result is far outside range or symptoms are significant (cycle irregularity, heavy bleeding, hot flashes/night sweats out of the expected life stage, new breast symptoms): follow up with your clinician for targeted serum testing (estradiol, estrone, SHBG), pelvic evaluation when appropriate, and a review of thyroid, iron, and metabolic markers.

FAQs

Does a higher 2-OH-E1 % mean lower breast-cancer risk?
Not necessarily. Research on ratios/percentages and risk is mixed. Use this marker to understand metabolism, not to predict risk or guide treatment by itself.

Can I fix a “low” 2-OH-E1 % with supplements?
Sometimes dietary changes (crucifers, fiber, whole-foods pattern) help. Supplements like DIM/I3C can alter metabolism but aren’t for everyone—work with your clinician and re-test rather than self-treating.

Is more 2-OH always better?
No. The key is balance and downstream methylation (adequate 2-methoxy). An extreme shift without good Phase II support isn’t the goal.

Key takeaways

  • 2-OH-E1 % shows the share of estrone routed to 2-hydroxylation; it’s a distribution metric, not a disease diagnosis.

  • Low %: relative shift toward 16-/4-OH; consider diet, lifestyle, and medication factors.

  • High %: more 2-OH routing—fine if 2-methoxy is adequate; if not, consider methylation support.

  • Aim for balanced pathways within your lab’s ranges, guided by your symptoms and clinician input.

2-OH-E1 % (Pre-menopausal)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond 2-OH-E1 % (Pre-menopausal) — 10,000+ markers explained
One 2-OH-E1 % (Pre-menopausal) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro